Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

BACKGROUND. The prognostic significance of baseline contrast enhancing tumor prior to second- or third-line therapy in recurrent glioblastoma (GBM) for overall survival (OS) remains controversial, particularly in the context of repeated surgical resection and/or use of anti-angiogenic therapy. In th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ellingson, Benjamin M., Harris, Robert J., Woodworth, Davis C., Leu, Kevin, Zaw, Okkar, Mason, Warren P., Sahebjam, Solmaz, Abrey, Lauren E., Aftab, Dana T., Schwab, Gisela M., Hessel, Colin, Lai, Albert, Nghiemphu, Phioanh L., Pope, Whitney B., Wen, Patrick Y., Cloughesy, Timothy F.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5193027/
https://ncbi.nlm.nih.gov/pubmed/27580889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now187
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados